Source: Annual Congress 2009 - Biomarkers, comorbidities and prognosis of COPD
Disease area: Airway diseases

Abstract

To investigate the prevalence and effects of chronic obstructive pulmonary disease (COPD) in patients with chronic heart failure (CHF) we examined 118 patients, ≥65 years, ≥10 pack-years with a new diagnosis of CHF and followed them for 13 ± 5.8 months. The diagnosis and classification of COPD were made according to GOLD Guidelines. The primary end point was death or hospitalization for exacerbations; death from any cause was also assessed. The association of COPD with time to primary end point occurrence was analyzed by Cox proportional hazards regression.
The prevalence of COPD was 30% (36/118). Only 2/118 patients had previously diagnosed COPD. The percent of patients given β-blockers (80% vs 89%, P = 0.1), and the optimized to CHF target dose of β-blockers (46.3% vs 59.7%, P = 0.1) were no different in patients with or without COPD. Death or hospitalization occurred in 41 (34.7%) patients, and was no different in patients with COPD and in the remaining (13, 36.1% versus 28, 34.1%, HR 1.08, 95% CI 0.56-2.1). By contrast, the mortality risk was double in patients with than in those without COPD (HR 2.33, 95% CI 0.87-6.21), although the mortality rate did not reach a significant difference (P = 0.08).
These results suggest that there is a marked prevalence of undiagnosed COPD in patients with CHF, and that concomitant COPD increases the risk of death in these patients. The prescription of β-blockers were no different in CHF patients with or without concomitant COPD.
Supported by the Ministry of Health, Chiesi Foundation, and CFR.

Rating:

Share or cite this content

Citations should be made in the following way:
P. Boschetto, A. Fucili, D. Beltrame, A. Potena, L. Ballerin, C. E. Mapp, L. M Fabbri, E. De Rosa, C. Ceconi, R. Ferrari (Ferrara, Modena, Italy). Chronic obstructive pulmonary disease in heart failure: prevalence, therapeutic and prognostic implications. Eur Respir J 2009; 34: Suppl. 53, 4466

Member's Comments

No comment yet.

Related content which might interest you: Unrecognised ventricular dysfunction in COPD Source: Eur Respir J 2011; 39: 51-58 Year: 2012 Unrecognised ventricular dysfunction in COPD Source: Eur Respir J 2012; 39: 51-58 Year: 2012 The prospective impact of chronic obstructive pulmonary disease on short-term prognosis of patients with chronic heart failure Source: Annual Congress 2010 - COPD: cardiovascular comorbidities Year: 2010 Chronic obstructive pulmonary disease does not increase the risk of ischaemic heart disease Source: Annual Congress 2009 - Prognosis and comorbidities in COPD Year: 2009 Prevalence of comorbidities in patients with chronic obstructive pulmonary disease in presence of heart failure Source: International Congress 2016 – Comorbidities and exacerbations in COPD Year: 2016 Acute coronary events during acute exacerbations of chronic obstructive pulmonary disease Source: Annual Congress 2007 - Clinical aspects in COPD Year: 2007 Hypoxia as a risk factor for arrhythmias in patients with chronic obstructive pulmonary disease and heart failure Source: International Congress 2019 – More and more COPD Year: 2019 Cardiac biomarkers and outcome in patients with acute exacerbation of chronic obstructive pulmonary disease Source: Annual Congress 2012 - COPD exacerbation Year: 2012 The difficulties of functional class heart failure assessment in the patients with concomitant chronic obstructive pulmonary disease Source: Annual Congress 2010 - COPD: cardiovascular comorbidities Year: 2010 Short-term outcomes in community heart failure patients with chronic obstructive pulmonary disease Source: Annual Congress 2011 - Comorbidities and management in primary care Year: 2011 Beta-blockade therapy in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure in the presence and absence of pulmonary hypertension Source: Annual Congress 2010 - COPD: management Year: 2010 Frequency of adverse consequences after spirography in patients with chronic obstructive pulmonary disease and concomitant ischemic heart disease Source: International Congress 2016 – Hospitalisation and comorbidities in chronic lung diseases Year: 2016 Influence of concomitant chronic heart failure on incorrect evaluation of chronic obstructive pulmonary disease assessment tests Source: International Congress 2019 – Cardiovascular comorbidities in COPD Year: 2019 Overall management of stable chronic obstructive pulmonary disease Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-48-0, page=258 Year: 2006 Prevalence, correlates and mortality impact of chronic obstructive pulmonary disease in end stage kidney disease Source: Annual Congress 2008 - COPD - clinical and epidemiological aspects Year: 2008 The characteristic of chronic renal dysfunction in patients with chronic obstructive pulmonary disease Source: International Congress 2016 – Biomarkers and phenotypes of COPD and comorbidities Year: 2016 Socioeconomic burden of chronic obstructive pulmonary disease Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-48-0, page=463 Year: 2006 Inflammatory biomarkers as outcome predictors of acute respiratory failure on top of chronic obstructive pulmonary diseases (COPD) Source: Annual Congress 2013 –Infection, sepsis and outcomes in ICU Year: 2013 The heart rate variability in patients with chronic obstructive pulmonary disease Source: Annual Congress 2008 - COPD Year: 2008 Chronic obstructive pulmonary disease: current burden and future projections Source: Eur Respir J 2006; 27: 397-412 Year: 2006